2024-05-02 10:48:20
(1) Terzić V (1,2), Miantezila Basilua J (1,2), Billard N (3), de Gastines L (1,2), Belhadi D (3,6), Fougerou-Leurent C (4), Peiffer- Smadja N (5,6), Mercier N (1,2), Delmas C (7), Ferrane A (7), Dechanet A (3), Poissy J (8), Espérou H (7), Ader F (9 ) ), Hites M (10), Andrejak C (11), Greil R (12), Paiva JA (13), Staub T (14), Tacconelli E (15), Burdet C (3), Costagliola D (16) , Mentré F (3,6), Yazdanpanah Y (3,5,17), Diallo A (1,2) and the study group Discovery. Cardiac adverse events and remdesivir in hospitalized patients with Coronavirus Disease 2019 (COVID-19): A post hoc safety analysis of the randomized Discovery trial.
Clin Infect Dis 2024 Mar 29:ciae170.
Clinical Trial Safety and Public Health, ANRS|Emerging Infectious Diseases, Paris, France
Clinical Research Safety Department, INSERM, Paris, France
Department of Epidemiology, Biostatistics and Clinical Research, Hospital Bichat, APHP, Paris, France
Pharmacology Unit, Rennes University Hospital; CIC Inserm 1414, Rennes University Hospital, Rennes, France
Department of Infectious Diseases, Bichat – Claude-Bernard Hospital, APHP, Paris, France
Paris Cité University, IAME, INSERM, Paris, France
Clinical Research Center, INSERM, Paris, France
University of Lille, Inserm U1285, Lille University Hospital, Intensive Care Unit, CNRS, UMR 8576 – UGSF – Structural and Functional Glycobiology Unit, Lille, France
Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, F-69004, Lyon, and International Center for Research in Infectiology (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon , F-69007, Lyon, France
Department of Infectious Diseases, Brussels University Hospital (HUB)-Erasme, Brussels, Belgium
Pulmonology Unit, University Hospital Amiens-Picardie, UR 4294 AGIR, Université Picardie Jules Verne, Amiens, France
IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunological Studies (SCRI-CCCIT); Cancer Cluster Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg, Austria
Intensive Care Medicine Service, Centro Hospitalar Universitário São João, Porto, Portugal
Center Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, Luxembourg
Infectious diseases, Dept. Diagnostics and Public Health, University of Verona, Verona, Italy
Sorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Paris, France
ANRS Emerging Infectious Diseases, Paris, France
(2) Gottlieb RL and Kalil AC. True detection of COVID-19 disease burden versus speculated antiviral cardiovascular risk requires a control group. Clin Infect Dis 2024 Mar 29:ciae172.
(3) https://cordis.europa.eu/project/id/101015736
Funded by Europe (The EU’s Horizon 2020 research and innovation program under grant agreement no. 101015736), Discovery is now research axis 1 in the EU-RESPONSE project (European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases, which brings together 22 partners (clinics, hospitals, universities, etc.) from 13 countries in the EU, Norway, Switzerland, Luxembourg and Turkey.
(4) Ader F, et al. Final results of the Discovery study of remdesivir for patients hospitalized with COVID-19. Lancet Infect Dis 2022;22(6):764-765.
(5) Gottlieb RL, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386(4):305-315.
(6) Amstutz A, et al. Effects of remdesivir in patients hospitalized with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med 2023; 11(5):453-464.
1714647901
#Discovery #Remdesivir #expose #hospitalized #patients #Covid19 #increased #risk #cardiac #effects
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
